Biomarkers
Let’s talk about BRCA variations and their impact on families. Read More ›
By Wayne Kuznar
Many biologic markers (biomarkers) are known to drive cancer and its progression, allowing scientists to develop new medications to target those biomarkers and increase survival for patients with lung cancer. Read More ›
By Wayne Kuznar
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›
By Dana Taylor
It has become increasingly clear that lung cancer can be caused by different factors, including some environmental chemicals. Lung cancer in never smokers under the microscope. Read More ›
By Dan Dean
Non-Hodgkin lymphoma survivor Dan Dean spoke with several experts about the advances in genomic testing, which have enabled oncologists to treat patients with new “targeted therapies” that fight cancer based on the specific features of a tumor. Read More ›
By Dana Taylor
Two experts discuss the advances made in lung cancer with the introduction of new immunotherapies, which have extended life for patients, and why testing for biomarkers is crucial. Read More ›
In January 2021, the FDA approved a new indication for Xalkori (crizotinib), an oral ALK inhibitor, for the treatment of young patients who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma and ALK mutation. Xalkori was previously approved for metastatic lung cancer and ALK or ROS1 mutation. Read More ›
By Dana Taylor
At the October 2020 conference of the European Society for Medical Oncology (ESMO), researchers presented information on new or recently approved targeted therapies and immunotherapies for lung cancer. Read More ›
In May 2020, the FDA approved Tabrecta, a new targeted therapy for the treatment of patients with metastatic non–small-cell lung cancer that is associated with the MET biomarker.
Read More ›
Non–small-cell lung cancer, or NSCLC, is the most common form of lung cancer, accounting for about 80% to 85% of all lung cancer cases in the United States.
Read More ›